Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 17/20 | 0.76 |
| ▸ | ICOSLG | O75144 | 4/20 | 0.53 |
| ▸ | ICOS | Q9Y6W8 | 4/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.53 |
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30342051 | 1.00 | CHUK (0.76) | CHUKICOSLGICOSIKBKBTYK2 | |
| SCHEMBL14253008 | 0.86 | CHUK (1.00) | CHUKICOSLGICOSIKBKBTYK2 | |
| SCHEMBL1797102 | 0.86 | CHUK (0.78) | CHUKICOSLGICOSIKBKBTYK2 | |
| SCHEMBL14253068 | 0.82 | CHUK (0.76) | CHUKICOSLGICOSIKBKBTYK2 | |
| SCHEMBL1798016 | 0.81 | CHUK (0.57) | CHUKICOSLGICOSIKBKBTYK2 | |
| SCHEMBL1799747 | 0.80 | CHUK (0.70) | CHUKICOSLGICOSIKBKBTYK2 | |
| SCHEMBL1799179 | 0.80 | CHUK (0.80) | CHUKICOSLGICOSIKBKBTYK2 | |
| SCHEMBL1799925 | 0.80 | CHUK (0.61) | CHUKICOSLGICOSIKBKB | |
| SCHEMBL1802859 | 0.79 | CHUK (0.57) | CHUKICOSLGICOSIKBKBTYK2 | |
| SCHEMBL1800230 | 0.79 | CHUK (0.59) | CHUKICOSLGICOSIKBKBTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112824387-B | 2-methyl nicotinate and preparation method and application thereof | 济南尚博生物科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-112824387-A | 2-methyl nicotinate and preparation method and application thereof | 济南尚博生物科技有限公司 | 2021-05-21 | — | — | CN | disclosed |
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2206713-A1 | Beta-carbolines useful for treating inflammatory disease | Millennium Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2206713-A1 | Beta-carbolines useful for treating inflammatory disease | Millennium Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7727985-B2 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727985-B2 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727985-B2 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100093713-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-1735311-B1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARM INC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-7348336-B2 | Substituted β-carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-7348336-B2 | Substituted β-carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| EP-1735311-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1611134-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005111037-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050239781-A1 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20040235839-A1 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. | 2004-11-25 | — | — | US | disclosed |
| WO-2004092167-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239781-A1 | Beta-carbolines useful for treating inflammatory disease | IL1B, IL1A, ADRA2B | CHUK 439/4885ICOSLG 3840/4885ICOS 3815/4885 |
| US-20040235839-A1 | Beta-carbolines useful for treating inflammatory disease | NFKBIA, IRAK2, IRAK1 | CHUK 6/4885ICOSLG 2264/4885ICOS 595/4885 |
| US-20100093713-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | NFKBIA, NFKB2, IKBKG | CHUK 8/4885ICOSLG 2200/4885ICOS 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.